Clinical Trial Update: Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib

View source ↗

Summary

This completed clinical trial updates hormone changes observed in women with Stage IIIB or Stage IV non-small cell lung cancer treated with erlotinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Northwestern University | Conditions: Advanced Nonsmall Cell Lung Cancer | Status: COMPLETED